BP1202
/ BrightPath Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 06, 2022
BP1202-NF2, a novel ADCC-enhancing CD39 antibody, induces destruction of regulatory T cells and enhances cytotoxic T lymphocytes induction.
(SITC 2022)
- "Ethics Approval The present study was approved by the Institutional Ethics Committee of BrightPath Biotherapeutics Co., Ltd. (approved number: ERD-01)."
Oncology • ENTPD1
1 to 1
Of
1
Go to page
1